The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo

This publication has 24 references indexed in Scilit:

• Live Subgroup B Respiratory Syncytial Virus Vaccines that Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates
  The Journal of Infectious Diseases, 1996
• Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
  Vaccine, 1995
• Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus
  Vaccine, 1995
• A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees
  Vaccine, 1994
• Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis
  Vaccine, 1994
• Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation
  Virus Research, 1994
• Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers
  Vaccine, 1993
• A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
  Vaccine, 1993
• Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization
  Vaccine, 1990
• The Association of the Temperature-Sensitive Phenotype with Viral Attenuation in Animals and Humans: Implications for the Development and Use of Live Virus Vaccines
  Clinical Infectious Diseases, 1979